All In Biotech

Drug Trial Radar · NCT05153239

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 705 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

705

Actual

Start

Jul 22, 2022

Primary completion

Apr 10, 2026

Study completion Apr 10, 2026

Sponsor

Lead sponsor
PharmaMarIndustry
Sponsor type
Industry
First posted
Dec 10, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

Conditions

  • Relapsed Small Cell Lung Cancer

Interventions

  • IrinotecanDrug

    Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

  • LurbinectedinDrug

    Lurbinectedin 3.2 mg/m² will be administered intravenously on Day 1 q3wk

  • IrinotecanDrug

    For patients aged \<70 years: irinotecan 350 mg/m² intravenously Day 1 q3wk For patients aged ≥70 years: irinotecan 300 mg/m² intravenously Day 1 q3wk

  • TopotecanDrug

    Topotecan 2.3 mg/m² oral or 1.5 mg/m² intravenously Days 1-5 q3wk

  • LurbinectedinDrug

    Lurbinectedin 2.0 mg/m² will be administered intravenously on Day 1 q3wk

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survivalTime frame: From the date of randomization to the date of death or last contact, up to 39 months

Locations

210 sites in 24 countries. Site status is shown where the registry gives one.

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Genesis Cancer and Blood

    Hot Springs, Arkansas

  • Florida Cancer Specialists - South

    Fort Myers, Florida

  • Florida Cancer Specialists - North

    St. Petersburg, Florida

  • Florida Cancer Specialists - Panhandle

    Tallahassee, Florida

  • Florida Cancer Specialists - East

    West Palm Beach, Florida

  • Duly Health and Care

    Joliet, Illinois

  • Norton Cancer Institue, Downtown

    Louisville, Kentucky

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Oncology Hematology West, PC (Grand Island)

    Grand Island, Nebraska

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists

    Omaha, Nebraska

  • FirstHealth Outpatient Cancer Center

    Pinehurst, North Carolina

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • MultiCare Regional Cancer Center - Tacoma

    Tacoma, Washington

  • Froedtert Hospital/Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Northern Beaches Hospital

    Frenchs Forest, Australia

  • Gosford Hospital GH - Central Coast Cancer Centre

    Gosford, Australia

  • Austin Hospital- Medical Oncology Unit

    Heidelberg, Australia

  • St John of God Murdoch Hospital

    Murdoch, Australia

  • Cancer Care Wollongong

    Wollongong, Australia

  • The Chris Obrien Lifehouse

    Camperdown, New South Wales, Australia

  • BRICC - Ballarat Health Services

    Ballarat Central, Victoria, Australia

  • Box Hill Hospital Eastern Health Clinical School

    Box Hill, Victoria, Australia

  • University Hospital Salzburg

    Salzburg, Austria

  • Medizinische Universitaet Wien

    Vienna, Austria

  • Algemeen Ziekenhuis AZ Klina - Borstkliniek

    Brasschaat, Belgium

  • Grand Hopital de Charleroi GHdC - Hopital Saint Joseph

    Charleroi, Belgium

  • Centre Hospitalier Chretien CHC - MontLegia

    Liège, Belgium

  • CHR de la Citadelle

    Liège, Belgium

  • CHU Liege

    Liège, Belgium

  • Az Sint Maarten Mechelen

    Mechelen, Belgium

  • Centre Hospitalier Universitaire (CHU) Ambroise Pare

    Mons, Belgium

  • Antwerp University Hospital

    Edegem, Antwerp, Belgium

  • Fundacao Pio XII - Hospital de Cancer de Barretos - Hospital de Amor

    Barretos, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia Ltda

    Ijuí, Brazil

  • Instituto Nacional de Cancer - Ministrio da Sade

    Rio de Janeiro, Brazil

  • Oncocentro-Centro de Oncologia do Parana

    Curitiba, Paraná, Brazil

  • Irmandade daSanta Casa de Misericordia de Porto Alegre

    Porto Alegre, Porto Alegre, Brazil

  • Hospital Sao Lucas da PUCRS

    Porto Alegre, Porto Alegre, Brazil

  • UPCO - Hospital de Clinicas de Porto Alegre

    Santa Cecília, Porto Alegre, Brazil

Showing 40 of 210 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.